Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
A new RNA therapeutics manufacturing company based in Sydney, Australia, launched on Thursday. Aurora Biosynthetics will produce plasmid DNA, mRNA and lipid nanoparticles. The company was founded by the New South Wales Government, which invested AU $200 million ($134 million) into Aurora’s first facility in Sydney, alongside RNA Australia and Myeloid Therapeutics.
Forge Biologics’ CEO Timothy Miller is stepping down after five years, the company said Tuesday. Chief financial officer John Maslowski will step in as the new CEO on Oct. 1. Forge Biologics was also named as the AAV development and manufacturing partner for the non-profit company Muscular Dystrophy Association’s Kickstart Program, according to a separate Monday release.
Contract research organization Arctoris has bought a laboratory in San Diego from Eli Lilly, the company said Thursday. No financial details were noted, but Lilly spent $90 million to build the facility back in 2017, which then opened in 2020. Dubbed the “Science Studio,” the lab housed technology to help scientists control experiments remotely.
Serán BioScience has expanded its facility in Bend, Oregon, from six to 14 suites, which boosts the company’s clinical manufacturing capacity by 130%, according to a Monday release. The expansion covers small molecules in late-stage clinical trials.
ReciBioPharm, the CDMO arm of Recipharm, has partnered with nucleic acid manufacturer Hongene Biotech, according to a Monday release. Hongene will provide its technology to ReciBioPharm for its plasmid, mRNA, sgRNA, LNP and fill-finish services.
Cellino Biotech has been awarded $25 million from the Advanced Research Projects Agency for Health, which is a part of the US Department of Health and Human Services. The funding will be used to build a new manufacturing platform, dubbed Nebula, that uses AI technology to produce personalized regenerative cells, according to a Tuesday release.
Cellares and Sony announced a new partnership Thursday to develop flow cytometry-based cell analysis technology to be added into Cellares’ cell therapy manufacturing platform Cell Shuttle.